BMRN

BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.

Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adithya Jayaraman - Evercore Inc. Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Alexandria Hammond - Wolfe Research, LLC Rakesh Kumar Joon Lee Olivia Brayer - Cantor Fitzgerald & Co., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the BioMarin Third Quarter 2026 Conference Call.

BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of HM15421/GC1134A SAN RAFAEL, Calif., Oct. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd.

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m.

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.